Nivolumab Plus Ipilimumab vs EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic HNSCC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651
J. Clin. Oncol 2022 Dec 06;[EPub Ahead of Print], RI Haddad, K Harrington, M Tahara, RL Ferris, M Gillison, J Fayette, A Daste, P Koralewski, B Zurawski, M Taberna, NF Saba, M Mak, A Kawecki, G Girotto, MA Alvarez Avitia, C Even, JGR Toledo, A Guminski, U Müller-Richter, N Kiyota, M Roberts, TA Khan, K Miller-Moslin, L Wei, A ArgirisFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.